The new location was established to ensure uninterrupted support for clients’ trials in both the United Kingdom and Europe if the UK leaves the European Union on Oct. 31, 2019, especially in the event of a no-deal Brexit.
Yourway, a clinical packager based in Allentown, PA, announced the opening of a new location in Bratislava, Slovakia, for storage and distribution services and secondary packaging capabilities. The new location was established to ensure uninterrupted support for clients’ trials in both the United Kingdom and Europe if the UK leaves the European Union on Oct. 31, 2019, especially in the event of a no-deal Brexit, according to an Oct. 14, 2019 press release.
“The new location in Europe mitigates the uncertainty of Brexit for our clients, in order to service their clinical trial needs. It includes Qualified Person (QP) release services within Europe prior to release for use in a clinical trial, as required by Clinical Trial Directive 2001/20/EC and Annex 13 to the European GMP Guide,” said Gulam Jaffer, Yourway president and founder, in the press release.
The company provides temperature-controlled solutions designed to protect clinical trial shipments from the time an order is received through to delivery, according to the release. Yourway also offers a fast, integrated supply chain to meet the needs of the market.
“Through our Project Managers and QP release personnel, and use of our global network of GMP depots, we can assure safe and timely delivery of clinical trial materials to patients,” said Jaffer.
Source: Yourway
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.